Table 1, Table 2, Table 3 and Table 4 present the characteristics of patients depending on the underlying disease, respectively. Table 1: cutaneous malignant melanoma; Table 2: Hodgkin lymphoma; Table 3: neuroblastoma; Table 4: other malignancies. Among 14/42 patients, the V600 mutation status in the BRAF gene was assessed—1/14 had the mutation detected. This evidence concerns the gene BRAF and Hodgkins lymphoma.